NeuroMetrix Announces Initial Commercial Shipment of SENSUS™ Pain Management System

  NeuroMetrix Announces Initial Commercial Shipment of SENSUS™ Pain Management
  System

Business Wire

WALTHAM, Mass. -- January 7, 2013

NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, a medical device
company focused on the diagnosis and treatment of the neurological
complications of diabetes, reported today that it had initiated commercial
shipment of its SENSUS Pain Management System which received final FDA
clearance on November 28, 2012. SENSUS is a transcutaneous electrical nerve
stimulator intended for the symptomatic relief and management of chronic
intractable pain. It offers physicians and their patients advanced nerve
stimulation technology in a light weight, low profile device worn on the upper
calf that is activated by the press of a single button.

“SENSUS was designed to address the clinical and lifestyle needs of people
with diabetes. Therefore, we believe that physicians treating patients with
painful diabetic neuropathy, a severe and debilitating form of chronic pain,
may find SENSUS to be a useful therapeutic option,” said Shai N. Gozani M.D.,
Ph.D., President and Chief Executive Officer of NeuroMetrix. “We are pleased
to be partnering with a growing network of durable medical equipment suppliers
who will be responsible for physician detailing, supplying product to
patients, and insurance billing. This will allow us to focus on our areas of
expertise which include product development, marketing programs, and clinical
studies.”

About NeuroMetrix

NeuroMetrixis an innovative medical device company that develops and markets
home use and point-of-care devices for the treatment and management of
diabetic neuropathies, which affect over 50% of people with diabetes. If left
untreated, diabetic neuropathies trigger foot ulcers that may require
amputation, cause disabling chronic pain, and increase the risk of falling in
the elderly. The annual cost of diabetic neuropathies has been estimated
at$14 billioninthe United States. The company’s products are used by
physicians and managed care organizations to optimize patient care and reduce
healthcare costs. The company markets the NC-stat^®DPNCheck™device, which is
a rapid, accurate, and quantitative point-of-care test for diabetic
neuropathy. This product is used to detect diabetic neuropathy at an early
stage and to guide treatment. The company also markets the SENSUS™ Pain
Management System for treating chronic pain, focusing on physicians managing
patients with painful diabetic neuropathy. The company has additional
therapeutic products in its pipeline. For more information, please visit
http://www.neurometrix.com.

Contact:

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
 
Press spacebar to pause and continue. Press esc to stop.